Astral Codex Ten

AstraZeneca

3 min read

AstraZeneca

Article

AstraZeneca is a recurring brand in the Astral Codex Ten archive, appearing 2 times across 2 issues between January 24, 2022 and May 18, 2022. The archive places it in contexts such as “US approves AstraZeneca vaccine”; “gotten money from AstraZeneca”. It most often appears alongside 538, ACX, ADHD.

Metadata

  • Category: Brands
  • Mention count: 2
  • Issue count: 2
  • First seen: January 24, 2022
  • Last seen: May 18, 2022

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

Grading My 2021 Predictions
January 24, 2022 · Original source
COVID 23. Fewer than 10K daily average official COVID cases in US in December 2021: 30% 24. Fewer than 50K daily average COVID cases worldwide in December 2021: 1% 25. Greater than 66% of US population vaccinated against COVID: 50% 26. India's official case count is higher than US: 50% 27. Vitamin D is not generally recognized (eg NICE, UpToDate) as effective COVID treatment: 70% 28. Something else not currently used becomes first-line treatment for COVID: 40% 29. Some new variant not currently known is greater than 25% of cases: 50% 30. Some new variant where no existing vaccine is more than 50% effective: 40% 31. US approves AstraZeneca vaccine: 20% 32. Most people I see in the local grocery store aren't wearing a mask: 60%
Lavender's Game: Silexan For Anxiety
May 18, 2022 · Original source
Professor Kasper seems like as legitimate and respectable a researcher as you can get for these kinds of things: head of the Department of Psychiatry at the University of Vienna, chair of the World Psychiatric Association’s pharmacology branch, editor of three good journals, various important and influential papers. Sure, he’s gotten “grants/research support, consulting fees and/or honoraria” from Schwabe. But he’s also gotten money from “Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, KRKA-Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre . . . and Servier”, and you don’t see him writing nearly as many glowing papers about their drugs. High-level academic psychiatrists academics are usually working with a bunch of drug companies and getting paid for that work, and this isn’t usually considered disqualifying to their credibility.
Inline links: Professor Kasper